Shanghai Fosun Pharmaceutical (02196) subsidiary Shanghai Fosun Pharmaceutical Industry plans to participate in the establishment of a private equity investment fund.

Shanghai Fosun Pharmaceutical (02196) announced that on October 28, 2025, the company's controlling subsidiary, Shanghai Fosun Pharmaceutical Industrial, signed a "Partnership Agreement" with 11 other investors to jointly invest in the establishment of a target fund with a total capital of 100 million RMB, with Shanghai Fosun Pharmaceutical as the LP cash contributor. The target fund will mainly focus on investing in enterprises in strategic emerging sub-sectors such as innovative chemical drugs, biopharmaceuticals (including vaccines), high-end medical devices (including IVD), traditional Chinese health supplements, synthetic biology, etc. This investment aims to leverage the strengths of both the Fosun Group and CHINARES PHARMA in the field of healthcare, and to expand the Group's channels in innovative drugs, biopharmaceuticals, high-end medical devices, synthetic biology, and other strategic emerging sectors in conjunction with local industrial policies and location advantages in Chengdu in order to achieve investment returns. After the establishment of the target fund, it will become a joint venture of the company.